tickerreport.com
Positivewww.tickerreport.com ·
vera therapeutics inc vera shares purchased by ubs group ag
EPU_ECONOMY_HISTORICTAX_MILITARY_TITLE_OFFICERTAX_FNCACT_OFFICERTAX_FNCACT_CHIEF_EXECUTIVE_OFFICER
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article reports institutional and insider trading activity in Vera Therapeutics, a biotech company. No direct commercial mechanism (e.g., product pipeline, regulatory decision, supply chain) is described. The impact is limited to equity positioning and sentiment for a single company, with no clear revenue or cost channel for the broader sector.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- UBS Group AG increased stake in Vera Therapeutics by 27.9% in Q4, owning 207,289 shares valued at $10,497,000.
- Deerfield Management Company owns 3,641,157 shares worth $105,812,000.
- Vera Therapeutics reported a loss of $1.69 per share for the quarter ending May 7, 2026, missing estimates by $0.36.
- Stock opened at $37.32, market cap $2.68 billion, 52-week range $18.76 to $56.05.
- Insiders including CEO Marshall Fordyce have sold shares recently.
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
fool.com
halozyme halo q1 2026 earnings transcript
economictimes.indiatimes.com
the rs 3 relief that wasnt why investors are dumping oil stocks after long awaited petrol diesel price hike
finance.yahoo.com